Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 601 to 650 of 872

TitleReference numberPublishedLast updated
Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neckTA473
Methylnaltrexone bromide for treating opioid-induced constipation (terminated appraisal)TA468
Idelalisib with ofatumumab for treating chronic lymphocytic leukaemia (terminated appraisal)TA469
Holoclar for treating limbal stem cell deficiency after eye burnsTA467
Pemetrexed for the maintenance treatment of non-small-cell lung cancerTA190
Cabozantinib for previously treated advanced renal cell carcinomaTA463
Baricitinib for moderate to severe rheumatoid arthritisTA466
Adalimumab and dexamethasone for treating non-infectious uveitisTA460
Roflumilast for treating chronic obstructive pulmonary diseaseTA461
Nivolumab for treating relapsed or refractory classical Hodgkin lymphomaTA462
Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young peopleTA455
Ustekinumab for moderately to severely active Crohn's disease after previous treatmentTA456
Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)TA454
Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation (terminated appraisal)TA452
Bortezomib for treating multiple myeloma after second or subsequent relapse (terminated appraisal)TA453
Etelcalcetide for treating secondary hyperparathyroidismTA448
Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive diseaseTA449
Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemiaTA450
Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemiaTA451
Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)TA444
Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDsTA445
Obeticholic acid for treating primary biliary cholangitisTA443
Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabineTA440
Ixekizumab for treating moderate to severe plaque psoriasisTA442
Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (terminated appraisal)TA240
Alectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (terminated appraisal)TA438
Elotuzumab for previously treated multiple myeloma (terminated appraisal)TA434
Tenofovir alafenamide for treating chronic hepatitis B (terminated appraisal)TA435
Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal)TA436
Ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy (terminated appraisal)TA437
Ustekinumab for treating active psoriatic arthritisTA340
Ustekinumab for treating moderate to severe plaque psoriasisTA180
Everolimus for advanced renal cell carcinoma after previous treatmentTA432
Apremilast for treating active psoriatic arthritisTA433
Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutationTA429
Sofosbuvir–velpatasvir for treating chronic hepatitis CTA430
Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomibTA427
Everolimus with exemestane for treating advanced breast cancer after endocrine therapyTA421
Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancerTA422
Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimensTA423
Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancerTA424
Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemiaTA425
Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemiaTA426
Ticagrelor for preventing atherothrombotic events after myocardial infarctionTA420
Dapagliflozin in combination therapy for treating type 2 diabetesTA288
Dapagliflozin in triple therapy for treating type 2 diabetesTA418
Apremilast for treating moderate to severe plaque psoriasisTA419
Nivolumab for previously treated advanced renal cell carcinomaTA417
Elbasvir–grazoprevir for treating chronic hepatitis CTA413
Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanomaTA414

Results per page

  1. 10
  2. 25
  3. 50
  4. All